Home/ Stocks/ MDGL

Madrigal Pharmaceuticals, Inc. Common Stock

MDGL XNAS

$510.04 -22.86 (-4.27%) ▼ 15-min delayed

Open

$535.00

High

$541.57

Low

$510.00

Volume

379.3K

Market Cap

$11.76B

About Madrigal Pharmaceuticals, Inc. Common Stock

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 915 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$311.34M	$-94,391,000	$-3.25
FY 2025	$958.40M	$-288,284,000	$-12.85
Q3 2025	$287.27M	$-114,190,000	$-5.08
Q2 2025	$212.80M	$-42,281,000	$-1.90

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for MDGL yet. Check out our latest market news or earnings calendar.

Get MDGL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Madrigal Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.